German report on benefit assessment a miss for drug industry; HTA grants strongest endorsement yet
This article was originally published in SRA
Executive Summary
A government report on the tough pricing and reimbursement system that Germany introduced under the AMNOG healthcare reform act has failed to address key problems with the system, according to Matthias Heck, Brussels representative for the BPI, a German pharmaceutical industry association. Separately, a drug has recently won the strongest endorsement yet from German health technology appraisal institute IQWiG for a product passing through the AMNOG system1-3.
You may also be interested in...
UK: Commercial Framework Sheds Light On Working With NHS And NICE
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
Time Is Ripe For Global Action On Orphan Biosimilars
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.
Time Is Ripe For Global Action On Orphan Biosimilars
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: